The Oncology Clinical Pathways Congress was held October 11-13 in Boston, MA. This year's meeting featured a variety of sessions and talks focused on improving cancer care quality through clinical pathways. It served as a forum for those involved in all stages of the pathway development process to ask questions, learn how to measure outcomes, and explore ways to partner and expand pathway programs.
Journal of Clinical Pathways was onsite to provide coverage of the most relevant and important sessions of the meeting.
Alexander B Olawaiye, MD, MRCOG, FACOG, FACS, University of Pittsburgh, presented on the emergence of PARP inhibitors and the rapidly expanding evidence base for ovarian cancer treatment.
Alan Balch, PhD, CEO, Patient Advocate Foundation, and Mishellene McKinney, RN, MHA, OCN, Roswell Park Comprehensive Cancer Center, spoke on how pathways can support high-quality care through more than just clinical decision support on therapy choices.
Rick Peters, MD, UT Austin Dell Medical School, and Mahek Shah, MD, Harvard Business School, presented on the role of technology in clinical pathways and shifting the identity of pathways from a retrospective view to a real-time predictive, prospective view.
Pathway leaders from Moffitt Cancer Center and US Oncology Network explained how their respective pathways would guide treatment for two hypothetical patient cases and how their physicians typically interact with the pathways.
Winston Wong, PharmD, offered the first look at the results of the second annual clinical pathways benchmarking survey of real-world pathway stakeholders.